Drug intelligence / Profile preview

fulvestrant + olaparib + palbociclib

Development stage: Unknown
Modality: Small Molecules
Administration: Intramuscular, Oral

Overview

A combination therapy consisting of fulvestrant (a selective estrogen receptor degrader), olaparib (a PARP inhibitor), and palbociclib (a CDK4/6 inhibitor). This combination is being investigated for the treatment of BRCA1/2-associated hormone receptor-positive (HR+), HER2-negative metastatic breast cancer. The therapy works by simultaneously targeting hormone signaling (fulvestrant), DNA repair mechanisms (olaparib), and cell cycle regulation (palbociclib).

Other names: HOPE combination therapy

Targets

GPER1 (G protein-coupled estrogen receptor 1)PARP3 (Poly(adp-ribose) polymerase 3)ESR1 (ERα)CDK6 (Cyclin-dependent kinase 6)CDK4 (Cyclin-dependent kinase 4)ESR2 (ERβ)PARP2 (Poly (adp-ribose) polymerase 2)

Beyond the preview

Go deeper on fulvestrant + olaparib + palbociclib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on fulvestrant + olaparib + palbociclib.

Explore the full profile